Inferra AI / Company / MIRM

Mirum Pharmaceuticals, Inc.

MIRM · Health Care

Last earnings Aug 5, 2026

AI analysis

Q2 2026 · reported Aug 5, 2026

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

Direction: Raised

Revenue$176 million

“1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 net product sales of $176 million 2026 net product sales guidance increased to $680 million to $700 million Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC Pre-NDA meeting held for volixibat in cholestatic pruritus due to PSC additional discussions planned before potential NDA submission, now targeted in H1 2027 Enrollment completed in VANTAGE study of volixibat in cholestatic pruritus due to PBC data expected Q1 2027 Conference call to provide business updates today, August 5 at 1 30 p.”

Revenue

“Q2 and Recent Highlights Commercial Raising Full Year Net Product Sales Guidance to $680 Million to $700 Million Second quarter 2026 global net product sales of $176.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Issued $690.0 million aggregate principal amount of 0.00% convertible senior notes due 2032.

Settled $237.2 million aggregate principal amount of 4.00% convertible senior notes due 2029, which represented approximately 75% of the then-outstanding notes.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

VISTAS was designed with FDA input as a pivotal study and met its primary endpoint with highly significant results

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 net product sales of $176 million 2026 net product sales guidance increased to $680 million to $700 million Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC Pre-NDA meeting held for volixibat in cholestatic pruritus due to PSC additional discussions planned before potential NDA submission, now targeted in H1 2027 Enrollment completed in VANTAGE study of volixibat in cholestatic pruritus due to PBC data expected Q1 2027 Conference call to provide business updates today, August 5 at 1 30 p.”

Revenue: “Q2 and Recent Highlights Commercial Raising Full Year Net Product Sales Guidance to $680 Million to $700 Million Second quarter 2026 global net product sales of $176.”

Revenue — Raised (“increased”)
“1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 net product sales of $176 million 2026 net product sales guidance increased to $680 million to $700 million Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC Pre-NDA meeting held for volixibat in cholestatic pruritus due to PSC additional discussions planned before potential NDA submission, now targeted in H1 2027 Enrollment completed in VANTAGE study of volixibat in cholestatic pruritus due to PBC data expected Q1 2027 Conference call to provide business updates today, August 5 at 1 30 p.”

Revenue — Raised (“increase”)
“Mirum delivered another strong quarter, with continued commercial momentum supporting an increase to our full-year net product sales guidance and launch readiness for the upcoming potential approval of zilurgisertib, said Chris Peetz, Chief Executive Officer of Mirum.”

Revenue — Raised (“Raising”)
“Q2 and Recent Highlights Commercial Raising Full Year Net Product Sales Guidance to $680 Million to $700 Million Second quarter 2026 global net product sales of $176.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Issued $690.0 million aggregate principal amount of 0.00% convertible senior notes due 2032.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Settled $237.2 million aggregate principal amount of 4.00% convertible senior notes due 2029, which represented approximately 75% of the then-outstanding notes.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

The Company s 4.00 % convertible senior notes due 2029 (the 2029 Notes ) are convertible at the option of the holders during the third quarter of 2026.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The Company s 0.00 % convertible senior notes due 2032 (the 2032 Notes ) are not convertible at the option of the holders during the third quarter of 2026.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Such amortization and accretion, as well as interest and dividends, are included in interest income.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Strategy & priorities

The FDA has accepted the NDA for zilurgisertib in FOP under Priority Review with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Mirum s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

The Company s development pipeline consists of the clinical-stage product candidate volixibat, MRM-3379, zilurgisertib and indication expansion opportunities for Livmarli.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Risks & headwinds

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum s business in general, risks and uncertainties associated with pharmaceutical development and commercialization in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the Securities and Exchange Commission.

SEC original ↗Mirum Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Legal Proceedings 43 Item 1A.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Any delays in the commencement or completion, or termination or suspension, of our clinical trials could result in increased costs for us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The Company s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 reflect the Company s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, tariffs and trade tensions, and foreign exchange rate fluctuations.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The amount of variable 9 Table of Content s consideration that is included in the transaction price may be constrained and is included in product sales, net only to the extent that it is considered probable that a significant reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

SEC original ↗Mirum Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Documents

Earnings deck slides

0 decks with slide view

Mirum Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors